论文部分内容阅读
目的 :探讨乙肝表面抗原(HBsAg)阳性孕妇孕期服用替比夫定后母婴阻断的效果,及其新生儿外周血中T细胞亚群和补体的变化。方法:选取40例HBsAg阳性孕妇,HBV-DNA载量≥1×106 U/m L,自愿在24~28周服用替比夫定为服药组,另选取40例孕期没有服用替比夫定的HBsAg阳性患者作为对照组,两组新生儿出生即刻抽取外周血检测HBV-DNA、T细胞亚群及补体。比较两组新生儿母婴阻断效果及外周血中T细胞亚群和补体的变化。结果:服药组新生儿外周血中T细胞亚群及补体与对照组比较差异无统计学意义(P>0.05),服药组新生儿阻断成功率100.0%,对照组阻断失败率7.5%。但是两组统计学差异不显著。结论:Hbs Ag阳性孕妇服用替比夫定对其新生儿T细胞亚群及补体水平无明显影响。
Objective: To investigate the effect of blocking telbivudine in pregnant women with HBsAg positive during pregnancy and the changes of T cell subsets and complement in their peripheral blood. Methods: Forty HBsAg-positive pregnant women with HBV-DNA load ≥1 × 106 U / m L were selected. Telbivudine was taken as the medication group voluntarily in 24-28 weeks. Another 40 pregnant women without taking telbivudine HBsAg positive patients as a control group, the two groups of newborns were taken immediately after the detection of peripheral blood HBV-DNA, T cell subsets and complement. The effects of maternal and neonatal blockade and changes of T lymphocyte subsets and complement in peripheral blood were compared between the two groups. Results: There were no significant differences in T lymphocyte subpopulation and complement in the peripheral blood of the newborn infants in the medication group compared with the control group (P> 0.05). The success rate of neonatal occlusion in the medication group was 100.0% and that of the control group was 7.5%. However, there was no significant difference between the two groups. Conclusion: Telbivudine in pregnant women with HbsAg positive had no significant effect on T cell subsets and complement levels in neonates.